News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amphora Discovery Corporation To Present Promising AKT Inhibitor Results At American Association for Cancer Research Annual Meeting



10/19/2005 5:12:42 PM

RESEARCH TRIANGLE PARK, N.C., April 15 /PRNewswire/ -- Amphora Discovery Corporation today announced the presentation of preclinical data on novel inhibitors of AKT1 at the 96th annual meeting of the American Association for Cancer Research in Anaheim, California April 17-21, 2005.

In the presentation titled "The anti-proliferative activity of potent and highly selective inhibitors of AKT1," Dr. Paul Steed, Amphora's Executive Director of Preclinical Biology, will present the latest findings from Amphora's preclinical AKT program. Inhibition of AKT enzymes (protein kinase B, PKB) has emerged as a promising new mechanism in the fight against cancer. Numerous companies are running discovery programs to find AKT inhibitors, but none have reported compounds advancing beyond the discovery stage. Amphora has identified highly potent and selective inhibitors of AKT1 using its novel pipeline approach. Amphora designed such absolute selectivity for AKT into its compounds as a strategy for avoiding off-target toxicological effects and for increasing the therapeutic index of its drug. In addition to precise selectivity for the target mechanism, Amphora's molecules exhibit a promising pharmacodynamic profile and favorable pharmacokinetic properties.

Amphora is using a best-in-class chemical biology platform to move programs to the IND stage faster and with a higher success rate than traditional approaches. Amphora's AKT program, which has proceeded rapidly from hit identification through preclinical development, highlights the advantages of using biologically relevant solution-state assays, a purified, characterized and drug-like screening library, and an industrialized drug discovery paradigm. Amphora's data quality and screening capacity are unparalleled in the industry, with more than 27 million directly comparable data points generated over the last three years.

In addition to Dr. Steed's presentation on Sunday, Amphora will present a poster titled "Early identification of chemical series with defined kinase inhibitor selectivity profiles," on Tuesday, April 19, 2005.

About Amphora

Amphora Discovery Corporation is a privately held pharmaceutical research company skilled in the science and art of pathway-based drug discovery. Its lead generation platform delivers unmatched precision, selectivity and data quality, which has produced well characterized proprietary new clinical entities for use in oncology, inflammation, metabolic diseases and neurological disorders. Amphora's most advanced compounds are preclinical candidates in the areas of oncology and inflammation which are exquisitely specific inhibitors for AKT1 and p38alpha respectively. Amphora is based in the Research Triangle Park, North Carolina, with offices in Los Altos, California. For more information, visit http://www.amphoracorp.com/ .

Amphora Discovery Corporation

CONTACT: Tracy Thompson of Amphora Corporate Communications,+1-919-287-6177, or Tracy.Thompson@amphoracorp.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES